Sanjay Ramakrishnan

Nov 29, 2024 | msn.com | Mona Bafadhel |Richard Russell |Sanjay Ramakrishnan

Continue reading More for You

Nov 29, 2024 | theconversation.com | Mona Bafadhel |Richard Russell |Sanjay Ramakrishnan

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone. Unfortunately, these drugs don’t work for everyone and they have significant levels of serious side-effects.

May 30, 2024 | erj.ersjournals.com | Sanjay Ramakrishnan |Brett Montgomery |Ian D Pavord

FootnotesConflict of interest: S. Ramakrishnan declares salary support from the Charlies Foundation for Research, speaker honoraria from AstraZeneca and GlaxoSmithKline, and conference travel support from AstraZeneca. B. Montgomery declares an unpaid membership of the Guidelines Committee of the Australian Asthma Handbook, a project of the National Asthma Council Australia.

Sep 1, 2023 | openres.ersjournals.com | Sanjay Ramakrishnan

Treatments for COPD exacerbations have not changed in the last 30 years. Despite fewer than 800 patients ever having been enrolled in placebo-controlled trials [1], systemic corticosteroids have become the main treatment of COPD exacerbations. Most of the trials were performed prior to the widespread use of inhaled corticosteroids. We know our treatment is ineffective. 28% of patients who are treated for a COPD exacerbation require re-treatment within a month [1].